Open AccessEffectiveness of Phosphodiesterase‐5 Inhibitor Therapy for Portopulmonary Hypertension
Author(s) -
Jolene H. Fisher,
Sindhu R. Johnson,
Cathy Chau,
Amie Kron,
John Granton
Publication year - 2015
Publication title -
canadian respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.675
H-Index - 53
eISSN - 1916-7245
pISSN - 1198-2241
DOI - 10.1155/2015/810376
Subject(s) - medicine , portopulmonary hypertension , cgmp specific phosphodiesterase type 5 , cardiology , intensive care medicine , portal hypertension , sildenafil , cirrhosis
Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom